Biodesix Delivers Strong Q2 2026 Results, Expanding Margins and Improving Operating Leverage
Biodesix, a leading healthcare company, recently released its second-quarter results for 2026, showcasing a remarkable quarter of growth and expansion. In a call with investors, Scott Hutton, Chief Executive Officer, highlighted the company's strong performance, driven by accelerating test volume growth and improved Average Selling Prices (ASPs) in their diagnostic testing business.
The total revenue reached $26.9 million, representing a 34% year-over-year growth, accompanied by solid operating discipline and execution. The company's diagnostic testing business witnessed a staggering 42% revenue increase, fueled by increased test volume growth and improved ASPs over the second quarter of 2025.
Total test volumes grew 38% year-over-year, attributed to increased adoption from both primary care and pulmonology. Specifically, primary care saw a remarkable 133% growth over the prior year, while pulmonology experienced a 31% increase. The company's efforts in expanding its presence in the primary care market have paid off, as it has seen strong demand for Nodify testing in patients with smaller lung nodules.
The publication of the largest lung nodule biomarker validation study to date in March played a significant role in driving up orders for Nodify CDT, which can detect cancer in nodules as small as 4 millimeters while maintaining a low false positive rate. This clinical evidence has led to increased utilization across the broader lung nodule continuum, with healthcare professionals who begin ordering Nodify CDT for smaller nodules subsequently increasing their use of both Nodify CDT and Nodify XL2 for patients with larger nodules.
The company's commitment to presenting and publishing clinical data for its on-market test continues to bear fruit. Recent presentations at the American Thoracic Society (ATS) annual meeting highlighted the real-world clinical value and economic advantages of lung nodule management programs that use Nodify Lung testing for risk stratification. This growing body of clinical evidence is driving deeper account penetration, increasing test utilization, and further validating the company's role in addressing this significant unmet clinical need.
Biodesix's strong Q2 2026 results demonstrate its commercial strategy's effectiveness and progress towards profitability. As the company continues to innovate and expand its presence in the healthcare market, it is clear that Biodesix is poised for continued success and growth in the years to come.
